Drug Repositioning for Ovarian Cancer Treatment: An Update

Author(s):

Maria Maddalena Cavalluzzi*, Maurizio Viale, Natalie Paola Rotondo, Valeria Ferraro and Giovanni Lentini   Pages 637 - 647 ( 11 )

Abstract:

Ovarian cancer (OC) is one of the most prevalent malignancies in female reproductive organs, and its 5-year survival is below 45%. Despite the advances in surgical and chemotherapeutic options, OC treatment is still a challenge, and new anticancer agents are urgently needed. Drug repositioning has gained significant attention in drug discovery, representing a smart way to identify new clinical applications for drugs whose human safety and pharmacokinetics have already been established, with great time and cost savings in pharmaceutical development endeavors. This review offers an update on the most promising drugs repurposable for OC treatment and/or prevention.

Keywords:

Drug repositioning, ovarian cancer, metformin, statins, bisphosphonates, lubeluzole.

Affiliation:

Graphical Abstract:

Read Full-Text article